Four Weeks on Mounjaro: What's Happening in Your Body Right Now

You've just finished pen one: here's what that means

Picture the moment: you pull the last used pen from the fridge and realise you have now been doing this for a full month. A reasonable question follows, have things worked? The honest answer is that four weeks on the 2.5mg starting dose is not the right moment to judge the medicine's full capability. The 2.5mg pen is a tolerability phase. Its primary job is to familiarise your gut, your appetite signalling, and your daily routine with tirzepatide before any therapeutic escalation begins.

That said, many people do notice something shifting. Portions feel like enough sooner. The pull towards a late-night snack is quieter. Some people lose a few kilograms; others lose very little at this dose. Both are normal. The tirzepatide overview on our site explains how the dual GIP and GLP-1 mechanism works and why the effect compounds as your dose increases, it is worth a read if you want the mechanism in plain language.

One practical thing you can do right now, in under a minute: photograph your pen before discarding it and note the date in your phone. When your prescriber asks how you tolerated the first dose, having a clear timeline means you can give a precise answer rather than a vague one. Small record-keeping habits pay dividends at your clinical review.

Side effects at four weeks: what's normal, what's settling, what warrants attention

Gastrointestinal symptoms are the most common early experience with Mounjaro. Nausea tends to peak in the first one to two weeks after starting or after a dose increase, then settles for most people. By week four, many find that the worst of it has passed, though individual responses vary considerably. Loose stools, constipation, indigestion and a general feeling of fullness that tips into discomfort are all reported, and all recognised by the NHS tirzepatide medicines page.

Fatigue and mild headache are also common early on, often linked to eating less and drinking less fluid than your body is used to. Keeping protein intake adequate and sipping water consistently through the day makes a genuine difference, not as a general wellness platitude, but because dehydration amplifies nausea and fatigue in particular.

What does warrant prompt medical attention is severe, persistent abdominal pain that spreads towards your back, with or without vomiting. This could indicate pancreatitis, which is a known but uncommon side effect flagged in the MHRA's January 2026 Drug Safety Update for GLP-1 medicines. If that describes what you are feeling, contact a healthcare professional the same day, do not wait to see if it passes. For anything less acute, our FAQs cover the most common questions prescribers hear, and our aftercare team is available seven days a week.

Weight loss at four weeks: keeping expectations calibrated

In the SURMOUNT-1 clinical trial, the most substantial weight reductions were recorded at higher doses over a longer timeframe, 72 weeks at doses up to 15mg. The full trial results are detailed in the original NEJM publication for anyone who wants to read the primary data. Four weeks at the lowest dose is a very different position from the endpoint that produced those headline figures.

That framing is not discouraging, it is accurate. People who do well on Mounjaro long-term are often the ones who build the right habits during these early weeks: eating enough protein, keeping alcohol low, staying active at whatever level is manageable. The medicine creates a window; what happens in that window still matters.

If you are reading this while already on Mounjaro and wondering what comes next, the six-week point is when many people approach their first dose review. If you have recently stopped and are trying to understand the implications, our page on four weeks off Mounjaro covers what the evidence says about what changes after discontinuation. And if cost is a factor in your thinking at this stage, the Mounjaro cost guide sets out the private pricing context clearly.

What happens at the clinical review before dose two

Before moving from 2.5mg to 5mg, a prescriber needs to be satisfied that you tolerated the first dose and that continuing is appropriate. At nume, that review happens before every repeat order, a real clinician reads your responses, not a form-processing system. The clinical team takes a considered view on whether to titrate, hold, or flag anything that needs discussing further.

This step exists for good reason. Rushing a dose increase when GI side effects are still significant usually makes them worse, not better. Holding steady for another four weeks at 2.5mg is sometimes the right clinical call, and a prescriber who knows your history is better placed to make that judgement than any protocol applied uniformly. Some people also use this period to research whether inositol is worth combining with Mounjaro, a question our dedicated page addresses in full. If you want to revisit what the first weeks of treatment typically look like before your review, our guide to what to expect at three weeks on Mounjaro is a useful point of reference. If you are thinking about starting treatment and want to understand the full process, checking your eligibility through a free consultation is the place to begin.